{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:56:21Z","timestamp":1781254581422,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02788-0","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:55:05Z","timestamp":1781247305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anlotinib combined with neoadjuvant chemotherapy for HR+\/HER2\u2212 breast cancer (ACNTBC): a prospective, single-arm, single-center phase II clinical study with real-world validation"],"prefix":"10.1038","volume":"11","author":[{"given":"Jiajun","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyi","family":"Zi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2788_CR1","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto, A. N. et al. Breast cancer statistics 2024. CA Cancer J. Clin. 74, 477\u2013495 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2788_CR2","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde, L. A. et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J. Clin. Oncol. 39, 1485\u20131505 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2788_CR3","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1200\/JCO.2003.01.136","volume":"21","author":"M Kaufmann","year":"2003","unstructured":"Kaufmann, M. et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J. Clin. Oncol. 21, 2600\u20132608 (2003).","journal-title":"J. Clin. Oncol."},{"key":"2788_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164\u2013172 (2014).","journal-title":"Lancet"},{"key":"2788_CR5","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaoncol.2020.2535","volume":"6","author":"D Yee","year":"2020","unstructured":"Yee, D. et al. Association of event-free and distant recurrence\u2013free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol. 6, 1355\u20131362 (2020).","journal-title":"JAMA Oncol."},{"key":"2788_CR6","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz, G. et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 30, 1796\u20131804 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2788_CR7","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1023\/A:1013128213451","volume":"12","author":"W Eiermann","year":"2001","unstructured":"Eiermann, W. et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol. 12, 1527\u20131532 (2001).","journal-title":"Ann. Oncol."},{"key":"2788_CR8","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1093\/annonc\/mds132","volume":"23","author":"E Alba","year":"2012","unstructured":"Alba, E. et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM\/2006-03, a multicenter, randomized, phase-II study. Ann. Oncol. 23, 3069\u20133074 (2012).","journal-title":"Ann. Oncol."},{"key":"2788_CR9","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1093\/annonc\/mdy448","volume":"29","author":"P Cottu","year":"2018","unstructured":"Cottu, P. et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann. Oncol. 29, 2334\u20132340 (2018).","journal-title":"Ann. Oncol."},{"key":"2788_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","volume":"26","author":"SA Hurvitz","year":"2020","unstructured":"Hurvitz, S. A. et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR+\/HER2- breast cancer. Clin. Cancer Res. 26, 566\u2013580 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2788_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.annonc.2020.10.471","volume":"32","author":"PA Fasching","year":"2021","unstructured":"Fasching, P. A. et al. Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann. Oncol. 32, 49\u201357 (2021).","journal-title":"Ann. Oncol."},{"key":"2788_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1513749","volume":"375","author":"HS Rugo","year":"2016","unstructured":"Rugo, H. S. et al. Adaptive randomization of veliparib\u2013carboplatin treatment in breast cancer. N. Engl. J. Med. 375, 23\u201334 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2788_CR13","first-page":"101700","volume":"63","author":"J Xue","year":"2025","unstructured":"Xue, J. et al. Neoadjuvant chidamide combined with chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (MUKDEN 05): a multicentre, single-arm, phase 2 trial. Lancet Reg. Health West Pac. 63, 101700 (2025).","journal-title":"Lancet Reg. Health West Pac."},{"key":"2788_CR14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","volume":"31","author":"F Cardoso","year":"2025","unstructured":"Cardoso, F. et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2- breast cancer: a randomized phase 3 trial. Nat. Med. 31, 442\u2013448 (2025).","journal-title":"Nat. Med."},{"key":"2788_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","volume":"31","author":"S Loi","year":"2025","unstructured":"Loi, S. et al. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat. Med. 31, 433\u2013441 (2025).","journal-title":"Nat. Med."},{"key":"2788_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"2788_CR17","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1200\/JCO.2005.03.4645","volume":"24","author":"SB Wedam","year":"2006","unstructured":"Wedam, S. B. et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 24, 769\u2013777 (2006).","journal-title":"J. Clin. Oncol."},{"key":"2788_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa1111097","volume":"366","author":"HD Bear","year":"2012","unstructured":"Bear, H. D. et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N. Engl. J. Med. 366, 310\u2013320 (2012).","journal-title":"N. Engl. J. Med."},{"key":"2788_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa1111065","volume":"366","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz, G. et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N. Engl. J. Med. 366, 299\u2013309 (2012).","journal-title":"N. Engl. J. Med."},{"key":"2788_CR20","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1093\/annonc\/mdu455","volume":"25","author":"G von Minckwitz","year":"2014","unstructured":"von Minckwitz, G. et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44\u2013GeparQuinto). Ann. Oncol. 25, 2363\u20132372 (2014).","journal-title":"Ann. Oncol."},{"key":"2788_CR21","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert, N. J. et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 29, 1252\u20131260 (2011).","journal-title":"J. Clin. Oncol."},{"key":"2788_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jsps.2011.12.001","volume":"20","author":"LD Sasich","year":"2012","unstructured":"Sasich, L. D. & Sukkari, S. R. The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab). Saudi Pharm. J. 20, 381\u2013385 (2012).","journal-title":"Saudi Pharm. J."},{"key":"2788_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen, G. et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J. Hematol. Oncol. 11, 120\u2013130 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2788_CR24","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-21-2241","volume":"28","author":"Y Su","year":"2022","unstructured":"Su, Y. et al. Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma. Clin. Cancer Res. 28, 793\u2013809 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2788_CR25","doi-asserted-by":"publisher","first-page":"100984","DOI":"10.1016\/j.jpha.2024.100984","volume":"14","author":"X Han","year":"2024","unstructured":"Han, X. et al. Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA\/ROCK signalling pathway. J. Pharm. Anal. 14, 100984 (2024).","journal-title":"J. Pharm. Anal."},{"key":"2788_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12916-022-02357-6","volume":"20","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS\/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy. BMC Med. 20, 155\u2013164 (2022).","journal-title":"BMC Med."},{"key":"2788_CR27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41392-024-02051-4","volume":"9","author":"J-W Wu","year":"2024","unstructured":"Wu, J.-W. et al. Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial. Signal. Transduct. Target. Ther. 9, 344\u2013354 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"2788_CR28","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41392-024-01992-0","volume":"9","author":"H Duan","year":"2024","unstructured":"Duan, H. et al. Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial). Signal. Transduct. Target. Ther. 9, 296\u2013304 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"2788_CR29","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1200\/JCO.2005.02.6187","volume":"24","author":"M Kaufmann","year":"2006","unstructured":"Kaufmann, M. et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J. Clin. Oncol. 24, 1940\u20131949 (2006).","journal-title":"J. Clin. Oncol."},{"key":"2788_CR30","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","volume":"24","author":"HD Bear","year":"2006","unstructured":"Bear, H. D. et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 24, 2019\u20132027 (2006).","journal-title":"J. Clin. Oncol."},{"key":"2788_CR31","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1200\/JCO.23.00435","volume":"41","author":"JK Litton","year":"2023","unstructured":"Litton, J. K. et al. Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: NeoSTEEP. J. Clin. Oncol. 41, 4433\u20134442 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2788_CR32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.annonc.2024.10.018","volume":"36","author":"L Huppert","year":"2025","unstructured":"Huppert, L. et al. Pathologic complete response (pCR) rates for patients with HR+\/HER2\u2212 high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. Ann. Oncol. 36, 172\u2013184 (2025).","journal-title":"Ann. Oncol."},{"key":"2788_CR33","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.ctrv.2014.05.006","volume":"40","author":"I K\u00fcmler","year":"2014","unstructured":"K\u00fcmler, I., Christiansen, O. G. & Nielsen, D. L. A systematic review of bevacizumab efficacy in breast cancer. Cancer Treat. Rev. 40, 960\u2013973 (2014).","journal-title":"Cancer Treat. Rev."},{"key":"2788_CR34","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","volume":"35","author":"WF Symmans","year":"2017","unstructured":"Symmans, W. F. et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J. Clin. Oncol. 35, 1049\u20131060 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2788_CR35","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-12-3628","volume":"19","author":"G von Minckwitz","year":"2013","unstructured":"von Minckwitz, G. et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin. Cancer Res. 19, 4521\u20134531 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2788_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/1078-0432.CCR-25-2487","volume":"32","author":"JK Zhao","year":"2026","unstructured":"Zhao, J. K. et al. First-line anlotinib plus anthracyclines and ifosfamide followed by anlotinib maintenance in advanced soft-tissue sarcoma: a phase II single-arm trial. Clin. Cancer Res. 32, 76\u201382 (2026).","journal-title":"Clin. Cancer Res."},{"key":"2788_CR37","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/cac2.70006","volume":"45","author":"Q He","year":"2025","unstructured":"He, Q. et al. Neoadjuvant chemotherapy plus anlotinib in the treatment of resectable head and neck squamous cell carcinoma: a pilot phase II trial. Cancer Commun. 45, 632\u2013636 (2025).","journal-title":"Cancer Commun."},{"key":"2788_CR38","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/j.clbc.2024.01.018","volume":"24","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. The efficiency and toxicity of anlotinib in combination with docetaxel followed by epirubicin and cyclophosphamide regimen as neoadjuvant treatment in IIB to IIIA triple negative breast cancer: a single-arm, multicenter, open-label, phase II study. Clin. Breast Cancer 24, e195\u2013e202 (2024).","journal-title":"Clin. Breast Cancer"},{"key":"2788_CR39","doi-asserted-by":"publisher","first-page":"102193","DOI":"10.1016\/j.xcrm.2025.102193","volume":"6","author":"L Zhang","year":"2025","unstructured":"Zhang, L. et al. Neoadjuvant anlotinib\/sintilimab plus chemotherapy in triple-negative breast cancer (NeoSACT): phase 2 trial. Cell Rep. Med. 6, 102193 (2025).","journal-title":"Cell Rep. Med."},{"key":"2788_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","volume":"9","author":"Y Sun","year":"2016","unstructured":"Sun, Y. et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J. Hematol. Oncol. 9, 105\u2013113 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"2788_CR41","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin, P. C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav. Res. 46, 399\u2013424 (2011).","journal-title":"Multivariate Behav. Res."},{"key":"2788_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/sim.70212","volume":"44","author":"G Hripcsak","year":"2025","unstructured":"Hripcsak, G. et al. Assessing covariate balance with small sample sizes. Stat. Med. 44, e70212 (2025).","journal-title":"Stat. Med."},{"key":"2788_CR43","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1002\/sim.7084","volume":"35","author":"PC Austin","year":"2016","unstructured":"Austin, P. C. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat. Med. 35, 5642\u20135655 (2016).","journal-title":"Stat. Med."},{"key":"2788_CR44","doi-asserted-by":"crossref","unstructured":"van der Wal W. M. & Geskus R. B.& R. B. Geskus. ipw: an R package for inverse probability weighting. J. Stat. Softw. 43, 1\u201323 (2011).","DOI":"10.18637\/jss.v043.i13"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02788-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02788-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02788-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:03:46Z","timestamp":1781251426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02788-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2788"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02788-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}